Cargando…

Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma

PURPOSE: In this phase I study, we evaluated the safety, biodistribution and dosimetry of [(89)Zr]Zr-DFO-girentuximab ((89)Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC). METHODS: Ten eligible patients received an intravenous administration of 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merkx, Robin I. J., Lobeek, Daphne, Konijnenberg, Mark, Jiménez-Franco, Luis David, Kluge, Andreas, Oosterwijk, Egbert, Mulders, Peter F.A., Rijpkema, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426244/ https://www.ncbi.nlm.nih.gov/pubmed/33651116 http://dx.doi.org/10.1007/s00259-021-05271-w

Ejemplares similares

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2015)

Biodistribution of Mesenchymal Stromal Cells Labeled with [(89)Zr]Zr-Oxine in Local Radiation Injuries in Laboratory Animals
por: Astrelina, Tatiana A., et al.
Publicado: (2023)

Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET
por: Rizvi, Saiyada N. F., et al.
Publicado: (2012)

(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
por: Al-Zubaidi, Mohammed, et al.
Publicado: (2022)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with (111)In-girentuximab
por: van Oostenbrugge, Tim J., et al.
Publicado: (2019)

Biodistribution and radiation dosimetry of (11)C-labelled docetaxel in cancer patients
por: van der Veldt, Astrid A. M., et al.
Publicado: (2010)

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
por: Basaco, Tais, et al.
Publicado: (2018)

Quantitative Biodistribution and Pharmacokinetics Study of GMP-Grade Exosomes Labeled with (89)Zr Radioisotope in Mice and Rats
por: Choi, Hojun, et al.
Publicado: (2022)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

Biodistribution PET/CT Study of Hemoglobin-DFO-(89)Zr Complex in Healthy and Lung Tumor-Bearing Mice
por: Kiraga, Łukasz, et al.
Publicado: (2020)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

Biodistribution of (89)Zr-DFO-labeled avian pathogenic Escherichia coli outer membrane vesicles by PET imaging in chickens
por: Li, Zhe, et al.
Publicado: (2022)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Preclinical Pharmacokinetics and Dosimetry of an (89)Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model
por: Krache, Anis, et al.
Publicado: (2022)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [(11)C]Metoclopramide
por: Bauer, Martin, et al.
Publicado: (2021)

Safety, biodistribution and radiation dosimetry of [(123)I]ioflupane in healthy Chinese volunteers
por: Zhang, Min, et al.
Publicado: (2023)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Preclinical animal research on therapy dosimetry with dual isotopes
por: Konijnenberg, Mark W., et al.
Publicado: (2011)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway
por: Schwarzenberg, Johannes, et al.
Publicado: (2010)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

Biodistribution of (89)Zr-oxine-labeled human bone marrow-derived mesenchymal stem cells by micro-PET/computed tomography imaging in Sprague–Dawley rats
por: Wang, Shuzhe, et al.
Publicado: (2022)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Development and evaluation of (89)Zr-trastuzumab for clinical applications
por: Mohammadpour-Ghazi, Fatemeh, et al.
Publicado: (2023)

Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer
por: Smaldone, Marc C, et al.
Publicado: (2012)

Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers
por: Avila-Rodriguez, M.A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_17bf10834nh5v7u310enruroh8